News & Updates

Extended ECG monitoring for 30 days significantly increases the detection rates of arrhythmias compared with the standard 24-hour monitoring period in patients with hypertrophic cardiomyopathy (HCM), according to the TEMPO-HCM study presented at EHRA 2023.

Treatment with dapagliflozin leads to lower incidence of total heart failure (HF) events and cardiovascular death, regardless of patient characteristics such as ejection fraction, according to a study.

Individuals with atrial high-rates episodes (AHREs) are at greater risk of progression to atrial fibrillation (AF). But the good news is that treatment with antiarrhythmic medication appears to have a protective effect both on AHRE burden and AF risk.

Individuals who were born preterm and large for gestational age are at increased risk of atrial fibrillation (AF) up to middle age, and the risk increase is independent of familial confounding factors, according to a multinational cohort study.

A three-step ablation strategy that systematically targets multiple proarrhythmogenic atrial structures appeared superior to pulmonary vein isolation (PVI) alone in patients with persistent atrial fibrillation (AF), according to 10-month results of a new study presented at EHRA 2023.

Among patients with atrial fibrillation (AF), statin use was associated with a significantly lower risk of stroke or transient ischaemic attack (TIA) compared with non-use, according to a study presented at EHRA 2023.